

2026 Taiwan Liver Cancer Association Annual Meeting

From Multi-omics to Curative Intent in the Era of Systemic Therapy
 May 16-17, 2026 11F, Room 1101, Evergreen International Convention Center

2026/05/16 Saturday (12:30 – 17:40)

Time	Topic	Speaker	Moderator
12:30-13:00	Registration		
13:00-13:30	Free paper award presentation	Chi-Jung Wu Ming-Feng Chiang I-Cheng Lee	Tsung-Jung Lin TLCA Deputy Secretary General Taipei City Hospital, Renai Branch
13:30-13:40	Opening remarks	Yi-Hsiang Huang TLCA President Chun-Yen Lin TLCA Annual Meeting Chairman	
Session 1. Precision Medicine Toolbox for HCC			
13:40-14:00	Single-cell atlas of the immune microenvironment in HCC	Shih-Yu Chen Institute of Biomedical Sciences, Academia Sinica	Chun-Jen Liu National Taiwan University Hospital
14:00-14:20	Transcriptomics & spatial biology toward clinically usable biomarkers	Hsuan Liu Chang Gung University	Chia-Yen Dai Kaohsiung Medical University, Chung-Ho Memorial Hospital
14:20-14:40	Microbiome modulation and FMT to enhance immunotherapy efficacy in HCC	Pei-Chang Lee Taipei Veterans General Hospital	Chia-Chi Wang Taipei Tzu Chi Hospital
14:40-15:00	Radiomics for treatment response prediction and decision support: from model validation to workflow	I-Cheng Lee TLCA Secretary General Taipei Veterans General Hospital	Pin-Nan Cheng National Cheng Kung University Hospital
15:00-15:20	Coffee Break		
Session 2. Curative Intent After Systemic Therapy			
15:20-15:40	The role of ablation in the era of systemic treatment for advanced HCC	Hung-Wei Wang China Medical University Hospital	Ming-Jong Bair Taitung MacKay Memorial Hospital
15:40-16:05	Optimal Neoadjuvant Immunotherapy Trial Design in HCC: Less Is More	Ying-Chun Shen NTU Cancer Center	Ann-Lii Cheng Honorary Hospital Director NTU Cancer Center
16:05-16:25	Immunotherapy as a Bridging or Downstaging Strategy Before Liver Transplantation	Jin-Chiao Lee Linkou Chang Gung Memorial Hospital	Gar-Yang Chau Taipei Veterans General Hospital
16:25-16:45	When to transfer patients to liver transplantation after systemic therapy	Ming-Che Lee Shuang Ho Hospital	Jiunn-Chang Lin MacKay Memorial Hospital
16:45-17:05	From Curative Intent to Combination Strategies: The Taiwan Experience in Unresectable HCC Treatment with Selective Internal Radiation Therapy (SIRT)	Chien-An Liu Taipei Veterans General Hospital	Po-Chin Liang National Taiwan University Hospital
Satellite Symposium			
17:05-17:40	Roche symposium		
18:30-21:00	GALA DINNER		



主辦單位:



協辦單位:



2026

Taiwan Liver Cancer Association Annual Meeting

From Multi-omics to Curative Intent in the Era of Systemic Therapy
May 16-17, 2026 11F, Room 1101, Evergreen International Convention Center

2026/05/17 Sunday (08:00 – 15:20)

Time	Topic	Speaker	Moderator
08:00-08:30	Registration		
08:30-08:50	TLCA assembly meeting		
Session 3. KLCA-TLCA Joint Symposium			
09:00-09:20	How to predict treatment response or prognosis in ICI-treated HCC patients	Do Young Kim Yonsei University, Seoul, Korea	June Sung Lee KLCA President Inje University Ilsanpaik Hospital, Goyang, Korea
09:20-09:40	Locoregional alternatives for TACE-unsuitable HCC: Taiwan perspective (HAIC/SBRT/Proton/TARE/Histotripsy)	Chien-Hung Chen NTU Cancer Center	Yi-Hsiang Huang TLCA President Taipei Veterans General Hospital
09:40-10:00	Y90 for HCC in Korea	Hyo-Cheol Kim Seoul National University Hospital, Seoul, Korea	June Sung Lee KLCA President Inje University Ilsanpaik Hospital, Goyang, Korea
10:00-10:10	Panel discussion		June Sung Lee and Yi-Hsiang Huang
10:10-10:15	Group Photo	TLCA & JLCA & KLCA	
10:15-10:30	Coffee Break		
Session 4. JLCA Keynote Lecture			
10:30-11:00	Systemic therapy for HCC- Current status and future directions	Masatoshi Kudo Kindai University, Osaka, Japan	Chung-Kwe Wang TLCA Honorary President Kang-Ning General Hospital
11:00-11:25	Strategies to overcome immune-excluded microenvironment for HCC	Takahiro Kodama The University of Osaka, Osaka, Japan	Chun-Yen Lin TLCA Annual Meeting Chairman Chang Gung University
11:25-11:50	Strategies to enhance resectability and minimize recurrence risk in HCC	Kiyoshi Hasegawa The University of Tokyo, Tokyo, Japan	Wei-Chen Lee Linkou Chang Gung Memorial Hospital
Satellite Symposium			
12:00-12:35	AZ symposium		
12:35-13:10	Eisai / MSD symposium		
13:10-13:45	BMS / Ono symposium		
Session 5. Emerging Therapeutic Strategies Shaping the Future of HCC			
14:00-14:20	Therapeutic tools for MASLD that may change HCC risk	Jee-Fu Huang Kaohsiung Medical University, Chung-Ho Memorial Hospital	Yu-Lueng Shih Taichung Armed Forces General Hospital
14:20-14:40	Transforming HCC Management: The Expanding Role of radiotherapy in Clinical Practice	Bing-Shen Huang Linkou Chang Gung Memorial Hospital	Chao-Hung Hung Kaohsiung Chang Gung Memorial Hospital
14:40-14:50	Closing remark	Yi-Hsiang Huang TLCA President	
Session 6. TLCA Research Group (TRG) Progress Report			
14:50-15:20	TRG research updates	Ying-Chun Shen NTU Cancer Center	Shi-Ming Lin TLCA Honorary President LinKou Chang Gung Memorial Hospital

2026 Taiwan Liver Cancer Association Annual Meeting

From Multi-omics to Curative Intent in the Era of Systemic Therapy
 May 16-17, 2026 11F, Room 1101, Evergreen International Convention Center

Satellite Symposium

2026/05/16 Saturday (17:05-17:40)

Time	Topic	Speaker	Moderator
17:05-17:40	Roche symposium From Evidence to Excellence: Translating First-Line Immunotherapy into Real-World Success in Japan	Takahiro Kodama The University of Osaka, Osaka, Japan	Yi-Hsiang Huang TLCA President Taipei Veterans General Hospital

2026/05/17 Sunday (12:00-13:45)

Time	Topic	Speaker	Moderator
12:00-12:35	AZ symposium Optimizing HCC Management with the STRIDE Regimen: Evidence, Experience and Evolution	Po-Ting Lin Linkou Chang Gung Memorial Hospital	Kuan-Yang Chen Taipei City Hospital, Yang-Ming Branch
12:35-13:10	Eisai / MSD symposium LEnding Strength: Optimizing Treatment Strategy in HCC Care	Yen-Chen Chiu National Cheng Kung University Hospital	Chen-Chun Lin New Taipei Municipal TuCheng Hospital
13:10-13:45	BMS / Ono symposium Long-Term Survival Milestones in Advanced Hepatocellular Carcinoma Treated with Nivolumab Plus Ipilimumab	Hung-Wei Wang China Medical University Hospital	Cheng-Yuan Peng China Medical University Hospital



主辦單位:



協辦單位:

